Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases

by Thomas J Polascik
Published 2008-12-01

Zoledronic acid in the management of metastatic bone disease

by Thomas J Polascik, Vladimir Mouraviev
Published 2008-03-01

Most of patients with localized prostate cancer will be treated in the future? | Opinion: No

by Ariel A. Schulman, Thomas J. Polascik

Clinicopathological characteristics of surgically treated localized renal masses in patients previously exposed to chemotherapy

by Efrat Tsivian, Matvey Tsivian, Christina Sze, Ariel Schulman, Thomas J. Polascik

Engaging the primary care community to encourage appropriate prostate cancer screening

by Malhar P. Patel, Ariel Schulman, Kevin P. Shah, John B. Anderson, Thomas J. Polascik
Published 2018-01-01

Altered male physiologic function after surgery for prostate cancer: couple perspective

by Matvey Tsivian, Mayes Janice M., Tracey L. Krupski, Vladimir Mouraviev, Craig F. Donatucci, Thomas J. Polascik
Published 2009-12-01

Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance...

by Christina Sze, Efrat Tsivian, Kae Jack Tay, Ariel A. Schulman, Leah G. Davis, Rajan T. Gupta, Thomas J. Polascik
Published 2019-12-01

Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: a relationship which may depend on genetic variation in ALA metabolism.

by Maria Azrad, Kui Zhang, Robin T Vollmer, John Madden, Thomas J Polascik, Denise C Snyder, Mack T Ruffin, Judd W Moul, Dean Brenner, Robert W Hardy, Wendy Demark-Wahnefried
Published 2012-01-01